Product Details
VOGLIBOSE 0.3 MG + METFORMIN HYDROCHLORIDE 500 MG SR
Introduction : The combination of Voglibose 0.3 mg, and Metformin Hydrochloride 500 mg SR (sustained release) is a medication used for the management of type 2 diabetes.
Indication : Voglibose 0.3 mg, and Metformin Hydrochloride 500 mg SR (sustained release) tablet is indicated for the treatment of type 2 diabetes when diet and exercise alone do not provide adequate glycemic control.
Administration : The dosage may vary, and it should be determined by a healthcare professional based on the patients individual needs and response to treatment.
Storage : Store at a controlled room temperature between 15 and 30 degrees C (59 and 86 degrees F); protect from light and moisture
Side Effects : "Diarrhoea
Flatulence
Pneumatosis Intestinalis
Abnormal Liver Function
Nausea Or Vomiting
Dizziness"
Contraindications : Use of this medicine is not recommended during pregnancies as the possible effect on developing fetus is unknown. It is recommended to discontinue the consumption of this medicine if you are pregnant or planning to become pregnant. Consult your doctor before stopping the use of this medication so that an alternate medication can be prescribed.
Safety Advice / Warnings : "Patients should be monitored regularly for signs of hypoglycemia, especially when Voglibose + Glimepiride + Metformin is used in combination with other antidiabetic medications.
This medication should be used with caution in patients with renal impairment, as metformin is primarily excreted by the kidneys, and dose adjustments may be necessary to prevent adverse effects.
Voglibose + Glimepiride + Metformin should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Patients should be advised to adhere to a regular meal schedule and monitor blood sugar levels closely while taking this medication"
References : Voglibose - PubChem [Internet]. Pubchem.ncbi.nlm.nih.gov. 2021 [cited 03 December 2021]. Available from:
https://pubchem.ncbi.nlm.nih.gov/compound/444020
Product Information: GLUCOPHAGE(R) oral tablets, metformin HCl oral tablets. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2017.
Product Information: Metformin Juta oral tablet, metformin hydrochloride oral tablet. Juta Pharma GmbH (per AEMPS;Spain), Gutenbergstrasse 13, 24941 Flensburg, Germany, 2019."
Voglibose - DrugBank [Internet]. Drugbank.ca. 2021 [cited 3 December 2021]. Available from:
Mechanism of Action : Voglibose inhibits alpha-glucosidase enzymes in the small intestine, delaying the digestion and absorption of carbohydrates. This results in a reduction in postprandial blood glucose levels.
Metformin primarily works by reducing hepatic glucose production, enhancing insulin sensitivity in peripheral tissues, and improving glucose uptake by muscles, leading to reduced blood sugar levels.
Therapeutic : Anti Diabetic